![COVID-19 Vaccine Booster Shots (3rd Dose)|Ministry of Health, Labour and Welfare, government of Japan|厚生労働省 COVID-19 Vaccine Booster Shots (3rd Dose)|Ministry of Health, Labour and Welfare, government of Japan|厚生労働省](https://www.mhlw.go.jp/content/booster.png)
COVID-19 Vaccine Booster Shots (3rd Dose)|Ministry of Health, Labour and Welfare, government of Japan|厚生労働省
![Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1088/F2.medium.jpg)
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ
Department of Health (Philippines) - All fully vaccinated adults (18 years old and above) are now eligible to receive single-dose booster shots at least three months after the second dose of the
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://www.thelancet.com/cms/asset/f3be98d8-d68c-4273-a286-fc9e5079f0d6/gr1.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-01194-5/MediaObjects/41591_2020_1194_Fig1_HTML.png)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine
![AstraZeneca boss Soriot says do not rush needlessly into COVID booster vaccines -The Telegraph | Reuters AstraZeneca boss Soriot says do not rush needlessly into COVID booster vaccines -The Telegraph | Reuters](https://cloudfront-us-east-2.images.arcpublishing.com/reuters/IWY5OB4JJVMMDPUABIAWRELDB4.jpg)
AstraZeneca boss Soriot says do not rush needlessly into COVID booster vaccines -The Telegraph | Reuters
![I got AstraZeneca for my first dose. Which should I get for my second?' A COVID vaccination guide - Healthy Debate I got AstraZeneca for my first dose. Which should I get for my second?' A COVID vaccination guide - Healthy Debate](https://healthydebate.ca/wp-content/uploads/2021/06/i_got_astrazeneca_for_my_first_dose._which_vaccine_is_best_for_my_second_1_pager-scaled.jpg)
I got AstraZeneca for my first dose. Which should I get for my second?' A COVID vaccination guide - Healthy Debate
![Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1088/F1.medium.jpg)